ベンゾジアゼピン依存症
(Benzodiazepine dependence から転送)
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2023/11/13 07:37 UTC 版)
ベンゾジアゼピン依存症（ベンゾジアゼピンいそんしょう、Benzodiazepine dependence）とは、『精神障害の診断と統計マニュアル』第4版（DSM-IV）に従えば、耐性、離脱症状、薬物探索行動、有害な影響に反しての継続使用、不適切なパターンにおける使用、などのいずれか3つ以上を満たした状態である。しかしベンゾジアゼピン依存症の場合には、薬物による快い作用よりも不快な離脱反応を回避するために継続的に使用しているとみられている[1]。ベンゾジアゼピン依存症は、長期間の使用によって、低い治療用量においても[2]、依存行動がなくても形成される[3][4]。
- ^ de Wit, Harriet; Harriet de Wit, a, Roland R. Griffithsb (June 1991). “Testing the abuse liability of anxiolytic and hypnotic drugs in humans”. Drug and Alcohol Dependence 28 (1): 83–111. doi:10.1016/0376-8716(91)90054-3. PMID 1679388 2012年12月21日閲覧。.
- ^ Nutt, D.J. (1986-01-01). “Benzodiazepine dependence in the clinic: reason for anxiety”. Trends neurosci 7: 457–460. doi:10.1016/0165-6147(86)90420-7 2012年12月21日閲覧。.
- ^ Uzun, S.; Kozumplik, O.; Jakovljević, M.; Sedić, B. (Mar 2010). “Side effects of treatment with benzodiazepines”. Psychiatr Danub 22 (1): 90–3. PMID 20305598.
- ^ O'brien CP (2005). “Benzodiazepine use, abuse, and dependence”. J Clin Psychiatry 66 (Suppl 2): 28–33. PMID 15762817.
- ^ a b c Allison C, Pratt JA (May 2003). “Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence”. Pharmacol. Ther. 98 (2): 171–95. doi:10.1016/S0163-7258(03)00029-9. PMID 12725868.
- ^ a b Haddad, Peter; Deakin, Bill; Dursun, Serdar (2004-05-27). “Benzodiazepine dependence”. Adverse Syndromes and Psychiatric Drugs: A clinical guide. Oxford University Press. pp. 240-252. ISBN 978-0198527480
- ^ a b 中川敦夫ら 2011, p. 8.
- ^ Cloos JM, Ferreira V. (January 2009). “Current use of benzodiazepines in anxiety disorders”. Current Opinion in Psychiatry 22 (1): 90–95. doi:10.1097/YCO.0b013e32831a473d. PMID 19122540.
- ^ Licata SC; Rowlett JK (2008). “Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.”. Pharmacology Biochemistry and Behavior 90 (1): 74-89. PMID 18295321.
- ^ a b Puri, Basant K.; Tyrer, Peter (1998-08-28). “Clinical psychopharmacology”. Sciences Basic to Psychiatry (2nd ed.). Churchill Livingstone. pp. 155-157. ISBN 978-0443055140 11-07-2009閲覧。
- ^ a b c d Longo LP, Johnson B (April 2000). “Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives”. Am Fam Physician 61 (7): 2121-8. PMID 10779253.
- ^ Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM. et al. (Nov 2009). “Benzodiazepine dependence: focus on withdrawal syndrome.”. Ann Pharm Fr 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
- ^ a b Khong, E.; Sim, MG.; Hulse, G. (Nov 2004). “Benzodiazepine dependence.” (PDF). Aust Fam Physician 33 (11): 923-6. PMID 15584332.
- ^ 英国国立薬物乱用治療庁 2007.
- ^ a b Marriott S, Tyrer P. (August 1993). “Benzodiazepine dependence. Avoidance and withdrawal”. Drug safety: an international journal of medical toxicology and drug experience. 9 (2): 93-103. doi:10.2165/00002018-199309020-00003. PMID 8104417.
- ^ Petursson H (1994). “The benzodiazepine withdrawal syndrome”. Addiction 89 (11): 1455-9. doi:10.1111/j.1360-0443.1994.tb03743.x. PMID 7841856.
- ^ Galanter, Marc; Kleber, Herbert D. (2008-07-01). The American Psychiatric Publishing Textbook of Substance Abuse Treatment (4th ed.). United States of America: American Psychiatric Publishing Inc. p. 114. ISBN 978-1585622764
- ^ Poulos CX; Zack M (2004). “Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers”. Behavioural pharmacology 15 (7): 503-12. doi:10.1097/00008877-200411000-00006. PMID 15472572.
- ^ Kushner MG, Abrams K, Borchardt C (March 2000). “The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings”. Clin Psychol Rev 20 (2): 149-71. doi:10.1016/S0272-7358(99)00027-6. PMID 10721495.
- ^ Khanna JM, Kalant H, Weiner J, Shah G (1992). “Rapid tolerance and cross-tolerance as predictors of chronic tolerance and cross-tolerance”. Pharmacol. Biochem. Behav. 41 (2): 355-60. doi:10.1016/0091-3057(92)90110-2. PMID 1574525.
- ^ World Health Organisation - Assessment of Zopiclone
- ^ Allan AM, Baier LD, Zhang X (1992). “Effects of lorazepam tolerance and withdrawal on GABAA receptor-operated chloride channels”. J. Pharmacol. Exp. Ther. 261 (2): 395-402. PMID 1374467.
- ^ Rooke KC (1976). “The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice”. J Int Med Res 4 (5): 355-9. PMID 18375.
- ^ Reddy DS; Rogawski MA (2000-12-01). “Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself”. J Pharmacol Exp Ther 295 (3): 1241-8. PMID 11082461.
- ^ http://www.pubmedcentral.nih.gov/articlerender.fcgi-rendertype=abstract&artid=40853
- ^ Humphries, P; Pretorius, E; Naudé, H (2007). “Direct and indirect cellular effects of aspartame on the brain”. European Journal of Clinical Nutrition 62 (4): 451-462. doi:10.1038/sj.ejcn.1602866. ISSN 0954-3007.
- ^ Herlenius, Eric; Lagercrantz, Hugo (2004). “Development of neurotransmitter systems during critical periods”. Experimental Neurology 190: 8–21. doi:10.1016/j.expneurol.2004.03.027. ISSN 00144886.
- ^ http://thebrain.mcgill.ca/flash/a/a_01/a_01_m/a_01_m_ana/a_01_m_ana.html
- ^ a b c d e f The Ashton Manual 2002.
- ^ Heberlein, A.; Bleich, S.; Kornhuber, J.; Hillemacher, T. (Jan 2009). “[Benzodiazepine dependence: causalities and treatment options]”. Fortschr Neurol Psychiatr 77 (1): 7–15. doi:10.1055/s-0028-1100831. PMID 19101875.
- ^ Tyrer, Peter; Silk, Kenneth R., eds (2008-01-24). “Treatment of sedative-hypnotic dependence”. Cambridge Textbook of Effective Treatments in Psychiatry (1st ed.). Cambridge University Press. pp. 402. ISBN 978-0-521-84228-0
- ^ Karch, Steven B. (2006-12-20). Drug Abuse Handbook (2nd ed.). United States of America: CRC Press. p. 617. ISBN 978-0-8493-1690-6
- ^ a b c d e Committee on the Review of Medicines (1980-03-29). “Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines”. Br Med J 280 (6218): 910-2. doi:10.1136/bmj.280.6218.910. PMC 1601049. PMID 7388368.
- ^ a b c d e Polmear, Andrew (2008-03-31). Evidence-Based Diagnosis in Primary Care: Practical Solutions to Common Problems. United Kingdom: Butterworth-Heinemann. pp. 346-347. ISBN 978-0-7506-4910-0
- ^ ICD-10 (2007年). “Chapter V - Mental and behavioural disorders (F00-F99) - Mental and behavioural disorders due to psychoactive substance use, 10-F19)”. World Health Organisation. 2012年2月4日閲覧。
- ^ WHO Programme on Substance Abuse 1996, p. 21.
- ^ NHS Grampian 2006, pp. 4–5.
- ^ 英国精神薬理学会 2012, pp. 16–18.
- ^ Madhusoodanan S, Bogunovic OJ (September 2004). “Safety of benzodiazepines in the geriatric population”. Expert Opin Drug Saf 3 (5): 485–93. doi:10.1517/14740338.3.5.485. PMID 15335303.
- ^ Baillargeon L, Landreville P, Verreault R, Beauchemin JP, Grégoire JP, Morin CM (November 2003). “Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial” (PDF). CMAJ 169 (10): 1015–20. PMC 236226. PMID 14609970.
- ^ Casati A, Sedefov R, Pfeiffer-Gerschel T (2012). “Misuse of medicines in the European Union: a systematic review of the literature” (PDF). Eur Addict Res 18 (5): 228–45. doi:10.1159/000337028. PMID 22572594.
- ^ Authier, N; Balayssac, D; Sautereau, M; Zangarelli, A; Courty, P; Somogyi, AA; Vennat, B; Llorca, PM et al. (Nov 2009). “Benzodiazepine dependence: focus on withdrawal syndrome”. Ann Pharm Fr 67 (6): 408-13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
- ^ Panus, Peter; Katzung, Bertram G.; Jobst, Erin E.; Tinsley, Suzanne; Masters, Susan B.; Trevor, Anthony J. (November 2008). “Sedative-hypnotic drugs”. PHARMACOLOGY FOR THE PHYSICAL THERAPIST (1 ed.). McGraw-Hill Medical. p. 192. ISBN 978-0071460439
- ^ Tyrer, Peter; Silk, Kenneth R. (2008-01-24). Cambridge Textbook of Effective Treatments in Psychiatry (1st ed.). Cambridge University Press. p. 532. ISBN 978-0521842280
- ^ Morgan JD, Wright DJ, Chrystyn H (December 2002). “Pharmacoeconomic evaluation of a patient education letter aimed at reducing long-term prescribing of benzodiazepines”. Pharm World Sci 24 (6): 231–5. doi:10.1023/A:1021587209529. PMID 12512155.
- ^ Stewart R, Niessen WJ, Broer J, Snijders TA, Haaijer-Ruskamp FM, Meyboom-De Jong B (October 2007). “General Practitioners reduced benzodiazepine prescriptions in an intervention study: a multilevel application”. J Clin Epidemiol 60 (10): 1076–84. doi:10.1016/j.jclinepi.2006.11.024. PMID 17884604.
- ^ Niessen WJ, Stewart RE, Broer J, Haaijer-Ruskamp FM (February 2005). “[Reduction in the consumption of benzodiazepines due to a letter to chronic users from their own general practitioner]” (Dutch; Flemish). Ned Tijdschr Geneeskd 149 (7): 356–61. PMID 15751808.
- ^ Westbury, J; Jackson, S; Gee, P; Peterson, G (Oct 2009). “An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project”. Int Psychogeriatr 22 (1): 1–11. doi:10.1017/S1041610209991128. PMID 19814843.
- ^ Ashton, CH (1997). “Benzodiazepine Dependency”. In A Baum, S. Newman, J. Weinman, R. West, C. McManus. Cambridge Handbook of Psychology & Medicine. England: Cambridge University Press. pp. 376-80 2007年7月3日閲覧。
- ^ 英国国立医療技術評価機構 2004, p. 2.13.
- ^ Anthierens S, Habraken H, Petrovic M, Christiaens T (December 2007). “The lesser evil- Initiating a benzodiazepine prescription in general practice: a qualitative study on GPs' perspectives” (PDF). Scand J Prim Health Care 25 (4): 214-9. doi:10.1080/02813430701726335. PMID 18041658.
- ^ Granados Menendez MI, Salinero Fort MA, Palomo Ancillo M, Aliaga Gutierrez L, Garcia Escalonilla C, Ortega Orcos R (2006). “[Appropriate use of benzodiazepines zolpidem and zopiclone in diseases attended in primary care”] (Spanish; Castilian). Aten Primaria 38 (3): 159-64. PMID 16945275.[リンク切れ]
- ^ Barthelme B, Poirot Y (November 2008). “[Anxiety level and addiction to first-time prescriptions of anxiolytics: a psychometric study]” (French). Presse Med 37 (11): 1555-60. doi:10.1016/j.lpm.2007.10.019. PMID 18502091.
- ^ Professor Lader; Professor Morgan, Professor Shepherd, Dr Paul Williams, Dr Skegg, Professor Parish, Dr Peter Tyrer, Dr Inman, Dr John Marks (Ex-Roche), Peter Harris (Roche), Tom Hurry (Wyeth) (30th of October 1980 - 3rd of April 1981) (PDF). Benzodiazepine Dependence Medical Research Council headquarters, Closed until 2014 - Opened 2005. England: The National Archives.
- ^ Fruensgaard K (February 1976). “Withdrawal psychosis: a study of 30 consecutive cases”. Acta Psychiatr Scand 53 (2): 105–18. doi:10.1111/j.1600-0447.1976.tb00065.x. PMID 3091.
- ^ Lader M. (1991). “History of benzodiazepine dependence”. Journal of substance abuse treatment 8 (1–2): 53–9. doi:10.1016/0740-5472(91)90027-8. PMID 1675692.
- ^ Lucki I; Kucharik RF (1990). “Increased sensitivity to benzodiazepine antagonists in rats following chronic treatment with a low dose of diazepam”. Psychopharmacology 102 (3): 350-6. doi:10.1007/BF02244103. PMID 1979180.
- ^ Rickels K; Case WG, Schweizer EE, Swenson C, Fridman RB. (1986). “Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients”. Psychopharmacology bulletin 22 (2): 407-15. PMID 2877472.
- ^ Lader M. (December 1987). “Long-term anxiolytic therapy: the issue of drug withdrawal”. The Journal of clinical psychiatry 48: 12-6. PMID 2891684.
- ^ Miura S; Murasaki M (March 1992). “The future of 5-HT1A receptor agonists. (Aryl-piperazine derivatives)”. Progress in neuro-psychopharmacology & biological psychiatry 16 (6): 833-45. doi:10.1016/0278-5846(92)90103-L. PMID 1355301.
- ^ Meier PJ; Ziegler WH, Neftel K (1988-03-19). “[Benzodiazepine--practice and problems of its use]”. Schweizerische medizinische Wochenschrift 118 (11): 381-92. PMID 3287602.
- ^ Tsuji K, Tajima O (January 2012). “[Anxiolytic]” (Japanese). Nippon Rinsho 70 (1): 42–6. PMID 22413490.
- ^ Karch, Steven B. (2006-12-20). Drug Abuse Handbook (2nd ed.). USA: CRC Press. p. 35. ISBN 978-0849316906
- ^ Dieye AM, Sy AN, Sy GY, et al. (2007). “[Prescription of benzodiazepines by general practitioners in the private sector of Dakar: survey on knowledge and attitudes”] (French). Therapie 62 (2): 163-8. doi:10.2515/therapie:2007018. PMID 17582318.
- ^ Dieye AM, Sylla M, Ndiaye A, Ndiaye M, Sy GY, Faye B (June 2006). “Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists”. Fundam Clin Pharmacol 20 (3): 235-8. doi:10.1111/j.1472-8206.2006.00400.x. PMID 16671957.
- ^ Woody GE; Mc Lellan AT O'Brien CP (1979). “Development of psychiatric illness in drug abusers. Possible role of drug preference”. The New England journal of medicine. 301 (24): 1310–4. doi:10.1056/NEJM197912133012403. PMID 41182.
- ^ Sheehan MF, Sheehan DV, Torres A, Coppola A, Francis E (1991). “Snorting benzodiazepines”. Am J Drug Alcohol Abuse 17 (4): 457–68. doi:10.3109/00952999109001605. PMID 1684083.
- ^ Wetterling T, Backhaus J, Junghanns K (September 2002). “[Addiction in the elderly - an underestimated diagnosis in clinical practice?]” (German). Nervenarzt 73 (9): 861–6. doi:10.1007/s00115-002-1359-3. PMID 12215877.
[続きの解説]
- ベンゾジアゼピン依存症のページへのリンク
